A new blood test may soon help doctors identify Alzheimer’s disease earlier and more accurately than ever before. Developed by researchers at Washington University School of Medicine in St. Louis and Lund University in Sweden, the test can detect and stage the disease by measuring levels of a specific tau protein fragment called MTBR-tau243 in the blood.
In a study involving 902 participants, the test successfully distinguished between early and late stages of Alzheimer’s with 92% accuracy. This offers a less invasive and more accessible option compared to traditional diagnostic tools like PET scans and cerebrospinal fluid analysis.
Dr. Randall J. Bateman, one of the study’s senior authors, emphasized the test’s clinical promise: “This blood test clearly identifies Alzheimer’s tau tangles, which is our best biomarker measure of Alzheimer’s symptoms and dementia.”
The test’s accuracy and simplicity could help clinicians detect the disease in its early stages, when available treatments are most effective and pave the way for more timely interventions and personalized care.
Researchers are now working on making the test widely available, with hopes it will soon be integrated into routine clinical practice.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for guidance regarding medical conditions or treatment options.
